Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Anthera’s Sollpura flops after phase 3 Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by...
Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be ...
Severe Combined Immunodeficiency (SCID) is an inherited primary immunodeficiency disease (PIDD) that typically presents in infancy. It is characterized by profound immune deficiency condition resul...
AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung CancerThe exclusive collaboration for the study population allows the two companies to conduct a Phase ...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Advances in genetics research have sparked a surge in interest in gene therapy in derma...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
